³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå : ±â¼ú À¯Çüº°, Åõ¿© Çüź°, ¿ëµµº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Nanotechnology Drug Delivery Market, By Technology Type, By Mode of Administration, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1485862
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 284 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,518,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,464,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,855,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå ±Ô¸ð´Â 2023³â 891¾ï 9,843¸¸ ´Þ·¯·Î 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 9.81% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå - ½ÃÀå ¿ªÇÐ

¸¸¼ºÁúȯ·üÀÇ Áõ°¡·Î ÷´Ü ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡

¼¼°è ¸¸¼ºÁúȯÀÇ Áõ°¡·Î ÀÎÇØ ÷´Ü ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ºñ°¨¿°¼º Áúȯ(NCDs)Àº Àü ¼¼°è »ç¸Á¿øÀÎÀÇ ¾à 71%¸¦ Â÷ÁöÇϸç, ½ÉÇ÷°ü Áúȯ, ¾Ï, È£Èí±â Áúȯ, ´ç´¢º´ÀÌ ÁÖ¿ä ¿øÀÎÀ¸·Î ²ÅÈü´Ï´Ù. ÀÌ·¯ÇÑ °Ç°­ ¹®Á¦¿¡ ´ëÀÀÇϱâ À§ÇØ ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)°ú °°Àº ±â°üÀº ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 ¸¸¼ºÁúȯÀ» È¿°úÀûÀ¸·Î Ä¡·áÇÒ ¼ö Àִ ǥÀû ¾à¹°Àü´Þ ½Ã½ºÅÛÀ» °³¹ßÇϱâ À§ÇØ ³ª³ëÀÇÇÐ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, È­ÀÌÀÚ¿Í ³ë¹ÙƼ½º¿Í °°Àº Á¦¾à»çµéÀº ¸¸¼ºÁúȯ Ä¡·áÀÇ Ä¡·á ¼º°ú¿Í ȯÀÚ ¼øÀÀµµ¸¦ ³ôÀ̱â À§ÇØ ³ª³ëÅ×Å©³î·¯Áö ±â¹ÝÀÇ ¾à¹°Àü´Þ Ç÷§ÆûÀ» Àû±ØÀûÀ¸·Î ¸ð»öÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ ¾à¹°Àü´Þ ¼Ö·ç¼Ç¿¡ ´ëÇÑ °ü½ÉÀº ³ª³ë±â¼úÀÇ Áøº¸¸¦ ÅëÇØ ¸¸¼ºÁúȯÀÇ ºÎ´ãÀ» ÇØ°áÇÏ´Â °ÍÀÌ ½Ã±ÞÇÏ´Ù´Â °ÍÀ» ÀÔÁõÇϰí ÀÖ½À´Ï´Ù.

³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032) µ¿¾È ¸Å³â ¾à 9.81%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±â¼ú À¯Çü ¼¼ºÐÈ­¿¡ µû¶ó ³ª³ëÀÔÀÚ°¡ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµÆ½À´Ï´Ù.

Åõ¿© Çüź°·Î´Â 2023³â Á¤¸ÆÅõ¿©°¡ ÁÖ¿ä À¯ÇüÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â¿¡ °¡Àå Å« ¼öÀÍÀ» âÃâÇÒ ÁÖ¿ä ½ÃÀåÀÔ´Ï´Ù.

³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼®:

³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¼¼°è ½ÃÀåÀº ±â¼ú À¯Çü, Åõ¿© ÇüÅÂ, ¿ëµµ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº ±â¼ú À¯Çü¿¡ µû¶ó ³ª³ë°áÁ¤, ³ª³ëÀÔÀÚ, ¸®Æ÷Á», ¹Ì¼¿, µ§µå¸®¸Ó µî 5°¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. ³ª³ëÀÔÀÚ´Â ´ÙÀç´Ù´ÉÇÔ°ú Ç¥Àû ¾à¹°Àü´ÞÀÇ È¿°ú·Î ÀÎÇØ ³ª³ë±â¼ú ¾à¹°Àü´Þ ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ ±â¼ú À¯ÇüÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. Å©±â¿Í Ç¥¸é Ư¼ºÀ» Á¤¹ÐÇÏ°Ô Á¦¾îÇÒ ¼ö ÀÖ´Â ³ª³ëÀÔÀÚ´Â ¾ÈÁ¤¼º, »ýüÀûÇÕ¼º, Ä¡·á¿ë ÆäÀÌ·Îµå ¿ë·®À» Çâ»ó½ÃÄÑ ½ÃÀå º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº Åõ¿© ÇüÅ¿¡ µû¶ó °æ±¸, Á¤¸Æ, °æÇÇ, ÈíÀÔ µî 4°¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. Á¤¸Æ Åõ¿©´Â Àü½Å ¼øÈ¯¿¡ Á÷Á¢ Á¢±ÙÇÒ ¼ö ÀÖ°í ºü¸¥ ÀÛ¿ë ¹ßÇöÀ¸·Î ÀÎÇØ ³ª³ëÅ×Å©³î·¯Áö ±â¹Ý ¾à¹°Àü´Þ ½ÃÀå¿¡¼­ °¡Àå Áß¿äÇÑ Åõ¿© ÇüÅÂÀÔ´Ï´Ù. ÀÌ ÇüÅ´ ¾à¹°Àü´ÞÀ» Á¤¹ÐÇÏ°Ô Á¦¾îÇÒ ¼ö ÀÖ¾î Áï°¢ÀûÀÎ Ä¡·á °³ÀÔÀÌ ÇÊ¿äÇÑ ÁßÁõ Áúȯ¿¡ ÀûÇÕÇÕ´Ï´Ù.

³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®

ºÏ¹Ì´Â źźÇÑ ¿¬±¸ ÀÎÇÁ¶ó¿Í ÇコÄÉ¾î ¹× ³ª³ë±â¼ú¿¡ ´ëÇÑ ³ôÀº ÅõÀÚ·Î ½ÃÀåÀ» ¼±µµÇϰí ÀÖÀ¸¸ç, Amgen Inc. ¹× Johnson & Johnson°ú °°Àº ±â¾÷µéÀÌ Çõ½ÅÀûÀÎ ¾à¹°Àü´Þ ½Ã½ºÅÛÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â ½ºÀ§½º, ¿µ±¹°ú °°Àº ±¹°¡µéÀÌ »ó´çÇÑ ÁøÀüÀ» º¸À̰í ÀÖÀ¸¸ç, Roche Holding AG¿Í AstraZeneca PLC¿Í °°Àº ±â¾÷µéÀÌ ³ª³ëÅ×Å©³î·¯Áö ±â¹Ý ¼Ö·ç¼Ç¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, Àεµ¿Í ÀϺ»À» Áß½ÉÀ¸·Î ÇÑ ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·áºñ Áõ°¡¿Í ¸¸¼º ÁúȯÀÇ È®»êÀ¸·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, Sun Pharmaceutical Industries Ltd.¿Í ´ÙÄÉ´ÙÁ¦¾à°ú °°Àº Áö¿ª ±â¾÷µéÀº ³ª³ë±â¼úÀ» Ȱ¿ëÇÏ¿© ¸ÂÃãÇü ¾à¹°Àü´Þ ½Ã½ºÅÛÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù.

³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå - °æÀï »óȲ:

Amgen Inc., Johnson & Johnson, Roche Holding AG, AstraZeneca PLC¿Í °°Àº ÁÖ¿ä ±â¾÷µéÀÌ ³ª³ëÅ×Å©³î·¯Áö ±â¹ÝÀÇ »õ·Î¿î ¾à¹°Àü´Þ ½Ã½ºÅÛÀ» Çõ½ÅÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº Ä¡·á È¿°ú¿Í ȯÀÚ ¼øÀÀµµ¸¦ °³¼±Çϱâ À§ÇØ Ç¥ÀûÈ­µÇ°í È¿À²ÀûÀÎ ¾à¹°Àü´Þ Ç÷§Æû °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àü·«Àû Á¦ÈÞ, ÆÄÆ®³Ê½Ê ¹× Àμö´Â Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °­È­Çϰí Áö¸®Àû ÀÔÁö¸¦ È®´ëÇϱâ À§ÇØ ½ÃÀå ±â¾÷ÀÌ Ã¤ÅÃÇÏ´Â ÀϹÝÀûÀÎ Àü·«ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â ¼¼°è Á¦¾àȸ»ç È­ÀÌÀÚ(Pfizer)´Â ³ª³ë ÀǾàǰ Àü¹® »ý¸í°øÇÐ ±â¾÷ BIND Therapeutics¿ÍÀÇ Á¦ÈÞ¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Á¦ÈÞ´Â ³ª³ëÀÔÀÚ¸¦ ÀÌ¿ëÇÑ Ç¥Àû ¾à¹°Àü´Þ Ç÷§ÆûÀÎ BINDÀÇ Accurin ±â¼úÀ» Ȱ¿ëÇÏ¿© È­ÀÌÀÚÀÇ ¾Ï Ä¡·áÁ¦ Àü´ÞÀ» °­È­ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. À̹ø Á¦ÈÞ¸¦ ÅëÇØ È¿´ÉÀ» ³ôÀÌ°í ºÎÀÛ¿ëÀ» ÁÙÀÎ »õ·Î¿î ¾Ï Ä¡·áÁ¦ÀÇ °³¹ßÀ» ÃËÁøÇÒ ¼ö ÀÖ°Ô µÆ½À´Ï´Ù. ½Å»ý±â¾÷°ú ½ºÅ¸Æ®¾÷µéµµ ÆÄ±«Àû ±â¼úÀ̳ª Æ´»õ ¾à¹°Àü´Þ ¼Ö·ç¼ÇÀ» µµÀÔÇÏ¿© ½ÃÀå °æÀï¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´ÞÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ »ê¾÷ ¿¬±¸

Á¦5Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå »óȲ

Á¦7Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå : ±â¼ú À¯Çüº°

Á¦8Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå : Åõ¿© Çüź°

Á¦9Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå : ¿ëµµº°

Á¦10Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Nanotechnology Drug Delivery Market size was valued at USD 89,198.43 Million in 2023, expanding at a CAGR of 9.81% from 2024 to 2032.

The Nanotechnology Drug Delivery Market, leveraging nanoscale materials for targeted and efficient drug delivery, is poised for significant growth. The potential for enhanced drug efficacy and reduced side effects, increasing investments in nanomedicine research, and the rising prevalence of chronic diseases demanding novel therapeutic solutions drive market growth. However, market growth is restrained by challenges such as regulatory complexities, concerns regarding toxicity and biocompatibility, and high research and development costs. Opportunities lie in the development of novel nanocarriers for gene therapy, personalized medicine, and the utilization of nanotechnology for overcoming biological barriers, thereby expanding the scope of drug delivery applications.

Nanotechnology Drug Delivery Market- Market Dynamics

Rising Chronic Disease Rates Propel Demand for Advanced Nanotechnology Drug Delivery Solutions

The escalating rates of chronic diseases worldwide are driving the demand for advanced nanotechnology drug delivery solutions. For instance, according to the World Health Organization (WHO), non-communicable diseases (NCDs) account for approximately 71% of all deaths globally, with cardiovascular diseases, cancer, respiratory diseases, and diabetes being the leading causes. In response to this health challenge, organizations like the National Institutes of Health (NIH) in the United States are increasingly investing in nanomedicine research to develop targeted drug delivery systems that can effectively treat chronic conditions while minimizing side effects. Additionally, pharmaceutical companies such as Pfizer and Novartis are actively exploring nanotechnology-based drug delivery platforms to enhance therapeutic outcomes and patient compliance in the treatment of chronic diseases. This growing emphasis on innovative drug delivery solutions underscores the urgent need to address the burden of chronic illnesses through nanotechnology advancements.

Nanotechnology Drug Delivery Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.81% over the forecast period (2024-2032)

Based on Technology Type segmentation, Nanoparticles were predicted to show maximum market share in the year 2023

Based on Mode of Administration segmentation, Intravenous was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Nanotechnology Drug Delivery Market- Segmentation Analysis:

The Global Nanotechnology Drug Delivery Market is segmented on the basis of Technology Type, Mode of Administration, Application, and Region.

The market is divided into five categories based on Technology Type: Nanocrystals, Nanoparticles, Liposomes, Micelles, and Dendrimers. Nanoparticles have emerged as the dominant technology type in the Nanotechnology Drug Delivery Market due to their versatility and effectiveness in targeted drug delivery. With precise control over size and surface properties, nanoparticles offer enhanced stability, biocompatibility, and therapeutic payload capacity, driving their higher market adoption.

The market is divided into four categories based on the Mode of Administration: Oral, Intravenous, Transdermal, and Inhalation. Intravenous administration stands out as the primary mode in the Nanotechnology Drug Delivery Market, owing to its direct access to systemic circulation and rapid onset of action. This mode offers precise control over drug delivery, making it suitable for critical medical conditions requiring immediate therapeutic intervention.

Nanotechnology Drug Delivery Market- Geographical Insights

North America leads the market due to robust research infrastructure and high investments in healthcare and nanotechnology, with players like Amgen Inc. and Johnson & Johnson pioneering innovative drug delivery systems. In Europe, countries like Switzerland and the United Kingdom are witnessing significant advancements, with companies such as Roche Holding AG and AstraZeneca PLC investing in nanotechnology-based solutions. Meanwhile, the Asia Pacific region, led by India and Japan, is experiencing rapid growth fueled by increasing healthcare expenditure and rising chronic disease prevalence. Regional players like Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited are leveraging nanotechnology to develop tailored drug delivery systems.

Nanotechnology Drug Delivery Market- Competitive Landscape:

Leading companies such as Amgen Inc., Johnson & amp; Johnson, Roche Holding AG, and AstraZeneca PLC are at the forefront, investing significantly in research and development to innovate novel nanotechnology-based drug delivery systems. These companies focus on developing targeted and efficient drug delivery platforms to improve therapeutic outcomes and patient compliance. Additionally, strategic collaborations, partnerships, and acquisitions are common strategies employed by market players to strengthen their product portfolios and expand their geographic presence. For instance, in 2022, Pfizer, a global pharmaceutical company, announced a collaboration with BIND Therapeutics, a biotechnology company specializing in nanomedicine. The collaboration aimed to utilize BIND's Accurin technology, a targeted drug delivery platform utilizing nanoparticles, to enhance the delivery of Pfizer's oncology therapeutics. This partnership facilitated the development of novel cancer treatments with improved efficacy and reduced side effects. Emerging players and startups are also contributing to market competitiveness by introducing disruptive technologies and niche drug delivery solutions.

Recent Developments:

In September 2021, Nanovis announced the launch of the first and only bioceramic nanotube-enhanced pedicle screw system, nano fortifix(R), showcasing a pioneering nanotechnology-enhanced pedicle screw system with label claims to enhance bone growth

In July 2020, Curadigm Announces EUR 1 million in funding from BPI France's Deep Tech Program to Support the Development of the Nanoprimer Platform, highlighting a substantial investment in their Nanoprimer technology to enhance therapeutic bioavailability and efficacy across various drug classes

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NANOTECHNOLOGY DRUG DELIVERY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie Inc.

Amgen Inc.

AstraZeneca plc

Bristol-Myers Squibb Company

Celator Pharmaceuticals Inc

Celgene Corporation

Celsion Corporation

GlaxoSmithKline plc

Johnson & Johnson

Merck & Co., Inc.

Nanobiotix S.A.

Novartis International AG

Pfizer Inc.

Roche Holding AG

Sanofi S.A.

Teva Pharmaceutical Industries Ltd.

Others

GLOBAL NANOTECHNOLOGY DRUG DELIVERY MARKET, BY TECHNOLOGY TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL NANOTECHNOLOGY DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL NANOTECHNOLOGY DRUG DELIVERY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL NANOTECHNOLOGY DRUG DELIVERY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1.Nanotechnology Drug Delivery Market Overview

2.Executive Summary

3.Nanotechnology Drug Delivery Key Market Trends

4.Nanotechnology Drug Delivery Industry Study

5.Nanotechnology Drug Delivery Market: COVID-19 Impact Analysis

6.Nanotechnology Drug Delivery Market Landscape

7.Nanotechnology Drug Delivery Market - By Technology Type

8.Nanotechnology Drug Delivery Market - By Mode of Administration

9.Nanotechnology Drug Delivery Market - By Application

10.Nanotechnology Drug Delivery Market- By Geography

11.Key Vendor Analysis- Nanotechnology Drug Delivery Industry

12.360 Degree Analyst View

13.Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â